SGMO

2.47

6.93% 0.16

Handel nachbörslich: 2.48 0.010 +0.40%

Sangamo Therapeutics Inc (SGMO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.31

Offen:

$2.3

24-Stunden-Volumen:

13.47M

Relative Volume:

1.66

Marktkapitalisierung:

$515.36M

Einnahmen:

$176.23M

Nettoeinkommen (Verlust:

$-257.83M

KGV:

-1.7034

EPS:

-1.45

Netto-Cashflow:

$-246.00M

1W Leistung:

+20.49%

1M Leistung:

+26.67%

6M Leistung:

+448.28%

1J Leistung:

+581.57%

1-Tages-Spanne:

$2.2501

$2.53

1-Wochen-Bereich:

$2.042

$2.84

52-Wochen-Spanne:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Firmenname

Sangamo Therapeutics Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(510) 970-6000

Adresse

501 CANAL BLVD., RICHMOND, CA

Mitarbeiter

405

Twitter

@sangamotx

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

SGMO's Discussions on Twitter

Vergleichen Sie SGMO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SGMO Sangamo Therapeutics Inc	2.47	515.36M	176.23M	-257.83M	-246.00M	-1.47
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-13	Hochstufung	Truist	Hold → Buy
2024-12-10	Bestätigt	H.C. Wainwright	Buy
2023-11-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-04-28	Herabstufung	BofA Securities	Neutral → Underperform
2023-02-27	Hochstufung	Wedbush	Neutral → Outperform
2023-01-06	Herabstufung	BofA Securities	Buy → Neutral
2022-06-13	Fortgesetzt	Wedbush	Neutral
2021-05-04	Eingeleitet	RBC Capital Mkts	Outperform
2021-01-07	Fortgesetzt	Guggenheim	Neutral
2021-01-06	Eingeleitet	Stifel	Hold
2020-12-16	Fortgesetzt	H.C. Wainwright	Buy
2020-09-08	Eingeleitet	BofA Securities	Buy
2020-07-07	Eingeleitet	SunTrust	Buy
2019-08-26	Eingeleitet	H.C. Wainwright	Buy
2018-11-14	Herabstufung	JP Morgan	Overweight → Neutral
2018-11-09	Herabstufung	Guggenheim	Buy → Neutral
2018-10-10	Eingeleitet	Guggenheim	Buy
2018-06-20	Eingeleitet	BofA/Merrill	Buy
2017-11-15	Hochstufung	Piper Jaffray	Neutral → Overweight
2017-06-22	Fortgesetzt	Jefferies	Buy
2016-11-01	Herabstufung	Wedbush	Outperform → Neutral
2016-10-19	Herabstufung	Piper Jaffray	Overweight → Neutral
2015-12-04	Eingeleitet	Wells Fargo	Outperform
2015-10-23	Fortgesetzt	Jefferies	Buy
2013-05-03	Eingeleitet	BioLogic Equity Research	Sell
2011-02-23	Bestätigt	JMP Securities	Mkt Outperform
2010-07-29	Bestätigt	Wedbush	Outperform
2009-10-19	Eingeleitet	Brean Murray	Sell
2009-10-07	Bestätigt	Leerink Swann	Outperform
2009-08-25	Bestätigt	JMP Securities	Mkt Outperform

Alle ansehen

Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten

Dec 20, 2024

Astellas and Sangamo sign capsid deal for neurological diseases - MSN

Dec 20, 2024

Astellas partners with Sangamo on cutting-edge gene therapy - The Pharma Letter

Dec 20, 2024

Dec 19, 2024

Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development (NASDAQ:SGMO) - Seeking Alpha

Dec 19, 2024

Sangamo and Astellas link up in a $1.32B AAV deal - BioWorld Online

Dec 19, 2024

HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat

Dec 19, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap UpHere's What Happened - MarketBeat

Dec 19, 2024

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 19, 2024

Astellas hopes Sangamo's capsid can get gene therapies across the blood-brain barrier - FirstWord Pharma

Dec 19, 2024

Regarding Sangamo - substack.com

Dec 19, 2024

Sangamo Therapeutics, Inc. and Astellas Pharma Inc. Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases - Marketscreener.com

Dec 19, 2024

Sangamo Therapeutics Lands Major $1.3B Gene Therapy Deal with Astellas for Brain Disease Treatment - StockTitan

Dec 19, 2024

Dec 18, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Down 5%Time to Sell? - MarketBeat

Dec 18, 2024

Dec 17, 2024

Sangamo surges 24% after Roche ends development of hemophilia A gene therapy - MSN

Dec 17, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Shares Gap DownShould You Sell? - MarketBeat

Dec 17, 2024

Dec 16, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Upgraded by StockNews.com - MarketBeat

Dec 16, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Trading Up 25.5%Still a Buy? - MarketBeat

Dec 16, 2024

Sangamo shares surge on Roche gene therapy withdrawal By Investing.com - Investing.com Canada

Dec 16, 2024

Dec 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces hurdles - Investing.com

Dec 14, 2024

Dec 13, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Upgraded to "Buy" at Truist Financial - MarketBeat

Dec 13, 2024

Dec 10, 2024

The Analyst Landscape: 6 Takes On Sangamo Therapeutics - Benzinga

Dec 10, 2024

Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success - TipRanks

Dec 10, 2024

Dec 09, 2024

Jacobs Levy Equity Management Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Dec 09, 2024

Dec 08, 2024

mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.

Dec 08, 2024

Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30% - Simply Wall St

Dec 08, 2024

Dec 06, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Hold Rating by StockNews.com - MarketBeat

Dec 06, 2024

Dec 01, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Wasatch Advisors LP - MarketBeat

Dec 01, 2024

Nov 30, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat

Nov 30, 2024

Nov 23, 2024

GSA Capital Partners LLP Sells 587,544 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Nov 23, 2024

Nov 21, 2024

Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN

Nov 21, 2024

Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online

Nov 21, 2024

Nov 20, 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St

Nov 20, 2024

Nov 19, 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace

Nov 19, 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com

Nov 19, 2024

Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat

Nov 18, 2024

Nov 15, 2024

FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat

Nov 15, 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat

Nov 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada

Nov 14, 2024

Nov 13, 2024

Sangamo: Q3 Earnings Snapshot - Marketscreener.com

Nov 13, 2024

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN

Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia

Nov 13, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India

Nov 13, 2024